U.S. Wireless Telecom Stock News

T-Mobile US (TMUS) is stepping into a new chapter as Srini Gopalan prepares to take over as CEO while Mike Sievert moves to vice chairman, just as the company leans harder into retention and switching promos. See our latest analysis for T-Mobile US. Despite these leadership and strategy shifts, the 1 year total shareholder return of negative 7.11 percent and 30 day share price return of negative 6.43 percent show momentum has cooled. However, the 3 year total shareholder return of 47.91...

If you are wondering whether Lumen Technologies at around $7.63 is a turnaround bargain or a value trap, you are not alone, and that is exactly what we are going to unpack. Despite a bumpy week with a -11.7% move, the stock is roughly flat over 30 days at 0.1%, still up 36.0% year to date and 25.9% over the last year, with a striking 47.0% gain across three years despite a -10.7% five year drag. Those swings sit against a backdrop of ongoing efforts to streamline the business and refocus on...

Toro (TTC) just posted its FY 2025 third quarter numbers with revenue of $1.1 billion, basic EPS of $0.54 and net income of $53.5 million, putting another data point on what has been a mixed year so far. The company has seen quarterly revenue move from $1.3 billion in Q2 2025 and $1.0 billion in Q1 2025 while EPS has ranged from $1.37 in Q2 to $0.52 in Q1. This gives investors a clear view of how profit per share is tracking through the fiscal year as they weigh the current 7.4% net margin...

Teledyne Technologies (TDY) has been drifting slightly lower over the past week, even though its longer term returns still look solid. Let us unpack what might be driving that hesitation. See our latest analysis for Teledyne Technologies. At around $502.82, the recent 7 day share price return of negative 3.88 percent and 90 day share price return of negative 11.07 percent suggest momentum has cooled, even though the 1 year total shareholder return of 8.14 percent still points to a respectable...

One of the biggest stories of last week was how Duluth Holdings Inc. ( NASDAQ:DLTH ) shares plunged 27% in the week...

Some Dell Technologies Inc. ( NYSE:DELL ) shareholders may be a little concerned to see that the Director, Egon Durban...

Wondering if ResMed at around $245 a share is still good value or if the easy money has already been made? Let us unpack what the current price actually implies about the company. Over the last year ResMed has delivered a 7.8% return, with the stock up 7.6% year to date but only 0.5% over the past month and down 2.2% in the last week. This pattern suggests investors are still calibrating their view of its long term growth and risks. Recent headlines have focused on ResMed’s role in the fast...

We wouldn't blame PTC Inc. ( NASDAQ:PTC ) shareholders if they were a little worried about the fact that Kristian...

Accenture (ACN) has quietly outpaced the broader market over the past month, with the stock climbing about 13%, even as its year to date return remains down more than 21%. See our latest analysis for Accenture. At a share price of $273.74, Accenture’s recent 30 day share price return of 13.43% and 90 day gain of 14.27% suggest momentum is rebuilding, even though total shareholder return over the past year remains negative and longer term performance is modestly positive. If Accenture’s...

Wondering if Ingredion at around $111 a share is a bargain or a value trap? You are not alone, and this breakdown is designed to help you decide with confidence. The stock has bounced 2.8% over the last week and 4.4% over the past month, but it is still down 18.1% year to date and 19.3% over the last year, despite being up 61.4% over five years. That pattern reflects a market that has been rethinking Ingredion's role as a steady cash-generating ingredients supplier. Cyclical concerns and...

Many investors are wondering if Masimo at around $135 a share is a bargain in disguise or a value trap. This stock has been on a lot of watchlists lately. Despite a strong long term track record in medical technology, the stock is down about 2.9% over the last week, 7.7% over the last month, and roughly 20.5% over the past year. This has reset expectations and risk perceptions for many shareholders. Recent headlines have focused on Masimo's ongoing push into non invasive monitoring...

If you are wondering whether PayPal Holdings is a bargain or a value trap at today’s price, you are not alone. That is exactly what we are going to unpack. The stock is trading around $60.18, down 2.4% over the last week and about flat over the past month, but still sitting roughly 30% lower year to date and more than 70% below its 5 year level. Recent attention around PayPal has focused on its push to reinvigorate growth through new payment tools and partnerships, alongside ongoing efforts...

If you are wondering whether Marathon Petroleum still offers good value after its big run, or if you might be turning up late to the party, this breakdown will help you decide whether the current price makes sense. Even after a recent pullback, with the share price down 8.8% over the last week and 11.0% over the past month, Marathon is still up 23.3% year to date and 381.5% over five years, which highlights how strong the longer term story has been. Recent headlines have focused on Marathon...

Bristol Myers Squibb recently reported a series of oncology milestones, including FDA priority review for Opdivo plus AVD in advanced classical Hodgkin lymphoma and U.S. approval of Breyanzi for relapsed or refractory marginal zone lymphoma, alongside new hematology data at the ASH Annual Meeting. At the same time, the company extended its 94-year dividend record with a US$0.63 quarterly common dividend and secured new antibody-discovery collaborations, underscoring how late-stage...

Johnson & Johnson recently received U.S. FDA approval for RYBREVANT FASPRO™, the first subcutaneous amivantamab-based therapy for EGFR‑mutated non‑small cell lung cancer, covering all existing RYBREVANT® indications. The approval, backed by Phase 3 data showing at least comparable pharmacokinetics and signals of longer survival versus intravenous dosing, underscores how J&J is pairing oncology innovation with treatment convenience and potential system‑wide efficiency gains. We’ll now examine...

Hess Midstream recently issued full-year 2026 guidance, forecasting net income of US$650 million to US$700 million and outlining expected gathering, processing, and terminal volumes across its Bakken-focused midstream network. The company also reshaped its board leadership by appointing existing director Kristi McCarthy as Chair and adding Chevron executive Barbara Harrison, highlighting the deepening alignment with its largest customer and partner. Next, we’ll examine how this new 2026...

Wondering if Thermo Fisher Scientific is still worth buying at these levels, or if the market has already priced in the upside? This breakdown will help you see where the real value might be hiding. The stock is up 7.7% year to date and 9.3% over the last year, even after a recent pullback of around 2.8% over the past week and 2.3% over the last month. This suggests sentiment is positive but not euphoric. Recently, investors have been reacting to Thermo Fisher's ongoing role in high growth...

Wondering if Ecolab at around $261 a share is still a smart buy, or if the easy money has already been made? Let us unpack what the market might be pricing in and where the value really sits. The stock is up 1.7% over the last week, 2.5% over the past month, and 13.4% year to date, with a strong 87.4% gain over three years and 29.7% over five, which suggests investors have been steadily bidding up its quality story. Recently, investors have been paying closer attention to Ecolab as demand...

Ubiquiti Inc. recently reported that long-serving director Ronald A. Sege, who joined the board in 2012 and chaired its nominating and corporate governance committee while also serving on the audit and compensation committees, passed away on November 30, 2025, leaving his Class II board seat vacant. His death has reduced the audit committee to two independent directors, putting Ubiquiti out of compliance with New York Stock Exchange rules that require at least three independent audit...

Core Natural Resources (CNR) just cleared a major operational overhang, bringing its Leer South longwall mine back online after a combustion related shutdown and stabilizing productivity at West Elk, which may support a cleaner 2026 earnings picture. See our latest analysis for Core Natural Resources. The restart at Leer South has helped steady sentiment after a bruising stretch. A 90 day share price return of 8.46% contrasts with a weaker year to date and one year total shareholder return,...

Netflix (NFLX) has quietly slipped over the past month, even as its underlying business continues to generate solid growth in revenue and earnings. That disconnect is where the investment story gets interesting. See our latest analysis for Netflix. Over the past year Netflix’s share price has swung from strong gains to a sharp 1 month pullback of 16.9%, even as its 3 year total shareholder return of 218.4% shows that long term momentum remains very much intact. If Netflix’s shift into games...

SoFi Technologies (SOFI) has pulled back about 5% in the past week and 14% over the past 3 months, even though the stock is still up roughly 79% year to date. See our latest analysis for SoFi Technologies. The recent pullback looks more like a pause than a trend reversal, with SoFi’s 1 year total shareholder return of 68.13% and exceptional 3 year total shareholder return of 451.75% still signaling strong underlying momentum and improving sentiment around its growth story. If SoFi’s run has...

Ethos recently announced a partnership with Aflac Incorporated to distribute Aflac’s supplemental cancer insurance through Ethos’s fully digital platform, giving consumers quicker access to cash benefits for cancer-related expenses with no deductibles and simplified claims. The deal highlights how Aflac can plug its specialized supplemental health products into a third-party insurtech ecosystem, potentially broadening reach without rebuilding its own end-to-end digital distribution. We’ll...

Wondering if KeyCorp is still worth a closer look after its recent run, or if the value has already been priced in? This breakdown is designed to help you decide with confidence. The stock has climbed 0.5% in the last week, 21.0% over the past month and is now up 22.5% year to date, adding to a 29.7% gain over 1 year, 44.0% over 3 years and 63.4% over 5 years. That kind of momentum has been supported by a steady drip of positive sentiment around regional banks, regulatory clarity and...